Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

医学 内科学 肿瘤科 奥西默替尼 吉非替尼 肺癌 表皮生长因子受体 养生 培美曲塞 无进展生存期 埃罗替尼 临床终点 不利影响 随机对照试验 科克伦图书馆 化疗 癌症 顺铂
作者
Fei Yang,Wengang Zhang,Xiaoling Shang,Ni Liu,Xinchun Ma,Jing Qin,Yuqing Zhang,Yanguo Liu,Xiuwen Wang
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:177: 103760-103760 被引量:9
标识
DOI:10.1016/j.critrevonc.2022.103760
摘要

A growing number of regimens have been approved as first-line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. However, the optimal regimen has not been determined, especially for patients with different clinicopathological characteristics. Therefore, we performed this meta-analysis to compare the efficacy and safety of first-line treatments for patients with EGFR-mutated NSCLC based on clinicopathological characteristics, thereby providing evidence for individual patient clinical decision-making.The PubMed, Embase, Cochrane Library databases, and abstracts of ASCO, ESMO, and WCLC were searched from inception to 3 June 2021 to identify eligible randomized controlled trials (RCTs). The outcomes of progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs) were compared and ranked based on various clinicopathological characteristics among 14 regimens by network meta-analysis (NMA) and the surface under the cumulative ranking curve (SUCRA), respectively.25 RCTs were included, with a total of 6965 patients and 14 treatment regimens. The primary endpoint of all RCTs was PFS, and OS, ORR, and ≥3AEs were secondary endpoints. Regarding overall patients, the most distinct PFS benefit was observed in osimertinib (OSI), with the fewest ≥3AEs, whereas gefitinib plus pemetrexed-based chemotherapy (GEF+PB) provided the greatest benefit for OS. When considering EGFR mutation type, aumolertinib (AUM) and GEF+PB could be the optimal regimens in terms of PFS for patients with EGFR 19DEL and EGFR 21L858R, respectively. Notably, the efficacy of the 14 regimens for PFS varied across clinicopathological characteristics, with GEP+PB ranking first in Eastern Cooperative Oncology Group performance status (ECOG PS)= 1, Asian, age<65 and smoking subgroups, with AUM ranking first in ECOG PS= 0 and female subgroups, with ICO+PB ranking first in age ≥65 and no smoking subgroups, and with AFA+CET ranking first in the male subgroup. In terms of brain metastases, third-generation EGFR-TKI showed obvious superiority, with AUM and OSI optimally prolonging PFS in patients with and without brain metastases, respectively. In addition, GEF+PB is a superior alternative, ranking second in terms of PFS regardless of the presence of brain metastases.OSI and GEF+PB were the most two effective first-line regimens for overall patients, ranking first in PFS and OS, respectively. GEF+PB ranked first in terms of PFS in subgroups of EGFR 21L858R, ECOG PS= 1, Asian, age <65, and smoking. Meanwhile, AUM in subgroups of EGFR 19DEL, ECOG PS= 0, female, brain metastasis, OSI in the subgroup of without brain metastasis, ICO+PB in no smoking subgroup, and AFA+CET in male subgroup were the best options as for their evident superiority in PFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
任伟超发布了新的文献求助10
1秒前
U9A关闭了U9A文献求助
2秒前
牙牙完成签到,获得积分10
3秒前
3秒前
3秒前
5秒前
霸气乘风完成签到,获得积分10
6秒前
Jasper应助封从霜采纳,获得10
7秒前
小王发布了新的文献求助10
7秒前
小谢发布了新的文献求助20
8秒前
9秒前
Emma发布了新的文献求助10
10秒前
13秒前
zxt完成签到,获得积分10
14秒前
Thy发布了新的文献求助10
15秒前
16秒前
U9A发布了新的文献求助10
16秒前
一一发布了新的文献求助10
16秒前
16秒前
ledong发布了新的文献求助10
17秒前
17秒前
17秒前
18秒前
18秒前
20秒前
21秒前
U9A关闭了U9A文献求助
21秒前
JINCHANG完成签到,获得积分10
21秒前
Mayday发布了新的文献求助10
21秒前
23秒前
Kyle发布了新的文献求助30
23秒前
Allen发布了新的文献求助10
24秒前
LiRay发布了新的文献求助10
24秒前
Lily会发财发布了新的文献求助10
28秒前
26岁顶级保安完成签到,获得积分10
29秒前
无限猕猴桃完成签到,获得积分10
33秒前
33秒前
35秒前
Rondab应助东东采纳,获得10
36秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 1030
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3993587
求助须知:如何正确求助?哪些是违规求助? 3534299
关于积分的说明 11265206
捐赠科研通 3274074
什么是DOI,文献DOI怎么找? 1806303
邀请新用户注册赠送积分活动 883118
科研通“疑难数据库(出版商)”最低求助积分说明 809712